COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Valuation of Efficacy and Safety of Vitamin D3 Use in 80 Women Diagnosed With Fibromyalgia. Using FIQ Score and VAS.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03369379
Recruitment Status : Completed
First Posted : December 12, 2017
Last Update Posted : January 18, 2019
Information provided by (Responsible Party):
Luis Ivan Lozano Plata, Universidad Autonoma de Nuevo Leon

Brief Summary:
Fibromyalgia is a disease that significantly decreases the quality of life of people who suffer from it, has great repercussions at the socio-economic level due to the incapacity it produces. It is characterized by generalized pain, fatigue, sleep disorders, psychological stress and mental alterations, besides presenting painful points in different parts of the body to physical examination. Having few effective treatments is necessary to explore new options in their management to improve the general conditions of the patient. Previous studies have shown that patients with fibromyalgia have had low levels of vitamin D in the blood, a favorable response from post-vitamin D supplementation has been seen. This vitamin has been associated with pain pathways and with increased The perception of the same when it is in smaller amount. We will select patients with Fibromyalgia diagnosis from the external consultation of Rheumatology of the University Hospital "Dr. José Eleuterio González "of the UANL, over 18 years old who have not been previously supplemented with vitamin D, will initially be measured in blood of vitamin D, in addition to calcium as a safety measure, we will have a group that will only receive placebo and Another that will be supplemented with 50 thousand units weekly for 12 weeks, we will apply a questionnaire that measures pain scale and another one that measures the impact of the disease in the daily life of the patient, this will be done in a beginning and at the end of the 12 weeks .

Condition or disease Intervention/treatment Phase
Fibromyalgia D Vitamin Deficiency Drug: D3 Vitamin Other: Placebo Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Longitudinal, prospective, interventional, randomized.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double blind, the subject of study and researcher.
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo-controlled Trial to Measure the Efficacy and Safety of Vitamin D3 in Patients With Fibromyalgia.
Actual Study Start Date : May 31, 2017
Actual Primary Completion Date : December 31, 2017
Actual Study Completion Date : December 31, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: D3 Vitamin
In this group subjects will receive 1 vitamin D3 capsule of 50,000 units, each week, for 12 weeks.
Drug: D3 Vitamin
Subjects will receive a capsule of 50,000 units of vitamin D3 echa week for 12 weeks, basal levels of vitamin D will be taken and again at week 12.
Other Name: D3

Placebo Comparator: Placebo
In this group the subjects will receive 1 placebo capsule each week for 12 weeks.
Other: Placebo
Placebo pill

Primary Outcome Measures :

    Number of items in scale: The version from 19911 consisted of 10 items with 10 sub-items in the physical function scale (total items + sub-items = 19). The modified version from 1997 consists of 20 items with 11 physical function items (total items + sub-items = 30). The 2009 version consists of 21 items across the 3 domains of Function (n = 9), Overall Impact (n = 2), and Symptoms (n = 10).

    Subscales: Subscales from the 1991 version1 include physical function (10 sub-items), feel good (1 item), missed work (1 item), do job (1 item), pain (1 item), fatigue (1 item), rested (1 item), stiffness (1 item), anxiety (1 item), and depression (1 item).

Secondary Outcome Measures :
  1. VISUAL ANALOGUE SCALE [ Time Frame: 12 weeks ]
    Visual analogue scales (VAS) are psychometric measuring instruments designed to document the characteristics of disease-related symptom severity in individual patients and use this to achieve a rapid (statistically measurable and reproducible) classification of symptom severity and disease control.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Women diagnosed with Fibromyalgia from the outpatient clinic of the "Dr. José Eleuterio González" University Hospital of the Autonomous University of Nuevo Leon.
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female patients older than 18 years.
  • Patients who agree to participate in the study.
  • Those that meet the ACR 1990 and 2010 criteria for Fibromyalgia.
  • No previous use of vitamin D.
  • Patients diagnosed with primary or secondary fibromyalgia.

Exclusion Criteria:

  • Those subjects with previous use of vitamin D.
  • Known subjects with renal, liver, calcium metabolism disorders, malabsorption disorders, known neoplasms.
  • Subjects with serum calcium levels equal to or greater than 10.2 mg / dl.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03369379

Layout table for location information
Universidad Autónoma de Nuevo León
Monterrey, Nuevo León, Mexico, 66460
Sponsors and Collaborators
Universidad Autonoma de Nuevo Leon

Layout table for additonal information
Responsible Party: Luis Ivan Lozano Plata, Dr., Universidad Autonoma de Nuevo Leon Identifier: NCT03369379    
Other Study ID Numbers: RE16-00019
First Posted: December 12, 2017    Key Record Dates
Last Update Posted: January 18, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: It will be agreed with all participating researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Luis Ivan Lozano Plata, Universidad Autonoma de Nuevo Leon:
D Vitamin
Additional relevant MeSH terms:
Layout table for MeSH terms
Myofascial Pain Syndromes
Vitamin D Deficiency
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases
Deficiency Diseases
Nutrition Disorders
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents